Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma

Jorine De Haan; Johannes V. Van Thienen; Michael Casaer; Rebekka A. Hannivoort; Kristel Van Calsteren; Minke Van Tuyl; Mathilde M. Van Gerwen; Anne Debeer; Frédéric Amant; Rebecca C. Painter

doi:10.1159/000487128

Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma

Jorine De Haan, Johannes V. Van Thienen, Michael Casaer, Rebekka A. Hannivoort, Kristel Van Calsteren, Minke Van Tuyl, Mathilde M. Van Gerwen, Anne Debeer, Frédéric Amant, Rebecca C. Painter

Research output: Contribution to journal › Article › peer-review

21 Citations (Scopus)

Abstract

Targeted therapies have drastically changed the management of metastatic melanoma and have shown encouraging results on tumour progression but are also known for their high rates of adverse reactions. In general, targeted therapies are contraindicated during pregnancy due to concerns about teratogenesis. For the BRAF V600 inhibitor vemurafenib, the available literature about the effects on human pregnancy is limited to a single case report. In patients with metastatic melanoma that wish to continue their pregnancy, targeted therapies like vemurafenib offer the only possibility of improving maternal outcome. In this article, we report on a pregnant woman with metastatic melanoma who was treated with vemurafenib during pregnancy and experienced a fatal adverse reaction.

Original language	English
Pages (from-to)	119-124
Number of pages	6
Journal	Case Reports in Oncology
Volume	11
Issue number	1
DOIs	https://doi.org/10.1159/000487128
Publication status	Published - 19 Jan 2018
Externally published	Yes

Keywords

Metastatic melanoma
Pregnancy
Toxic epidermal necrolysis
Vemurafenib

Access to Document

10.1159/000487128

Cite this

@article{dec0bd2a92d44d75a9ad1ecc9772e798,

title = "Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma",

abstract = "Targeted therapies have drastically changed the management of metastatic melanoma and have shown encouraging results on tumour progression but are also known for their high rates of adverse reactions. In general, targeted therapies are contraindicated during pregnancy due to concerns about teratogenesis. For the BRAF V600 inhibitor vemurafenib, the available literature about the effects on human pregnancy is limited to a single case report. In patients with metastatic melanoma that wish to continue their pregnancy, targeted therapies like vemurafenib offer the only possibility of improving maternal outcome. In this article, we report on a pregnant woman with metastatic melanoma who was treated with vemurafenib during pregnancy and experienced a fatal adverse reaction.",

keywords = "Metastatic melanoma, Pregnancy, Toxic epidermal necrolysis, Vemurafenib",

author = "{De Haan}, Jorine and {Van Thienen}, {Johannes V.} and Michael Casaer and Hannivoort, {Rebekka A.} and {Van Calsteren}, Kristel and {Van Tuyl}, Minke and {Van Gerwen}, {Mathilde M.} and Anne Debeer and Fr{\'e}d{\'e}ric Amant and Painter, {Rebecca C.}",

note = "Publisher Copyright: {\textcopyright} 2018 The Author(s) Published by S. Karger AG, Basel.",

year = "2018",

month = jan,

day = "19",

doi = "10.1159/000487128",

language = "English",

volume = "11",

pages = "119--124",

journal = "Case Reports in Oncology",

issn = "1662-6575",

publisher = "S. Karger AG",

number = "1",

}

TY - JOUR

T1 - Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma

AU - De Haan, Jorine

AU - Van Thienen, Johannes V.

AU - Casaer, Michael

AU - Hannivoort, Rebekka A.

AU - Van Calsteren, Kristel

AU - Van Tuyl, Minke

AU - Van Gerwen, Mathilde M.

AU - Debeer, Anne

AU - Amant, Frédéric

AU - Painter, Rebecca C.

PY - 2018/1/19

Y1 - 2018/1/19

N2 - Targeted therapies have drastically changed the management of metastatic melanoma and have shown encouraging results on tumour progression but are also known for their high rates of adverse reactions. In general, targeted therapies are contraindicated during pregnancy due to concerns about teratogenesis. For the BRAF V600 inhibitor vemurafenib, the available literature about the effects on human pregnancy is limited to a single case report. In patients with metastatic melanoma that wish to continue their pregnancy, targeted therapies like vemurafenib offer the only possibility of improving maternal outcome. In this article, we report on a pregnant woman with metastatic melanoma who was treated with vemurafenib during pregnancy and experienced a fatal adverse reaction.

AB - Targeted therapies have drastically changed the management of metastatic melanoma and have shown encouraging results on tumour progression but are also known for their high rates of adverse reactions. In general, targeted therapies are contraindicated during pregnancy due to concerns about teratogenesis. For the BRAF V600 inhibitor vemurafenib, the available literature about the effects on human pregnancy is limited to a single case report. In patients with metastatic melanoma that wish to continue their pregnancy, targeted therapies like vemurafenib offer the only possibility of improving maternal outcome. In this article, we report on a pregnant woman with metastatic melanoma who was treated with vemurafenib during pregnancy and experienced a fatal adverse reaction.

KW - Metastatic melanoma

KW - Pregnancy

KW - Toxic epidermal necrolysis

KW - Vemurafenib

UR - http://www.scopus.com/inward/record.url?scp=85042136446&partnerID=8YFLogxK

U2 - 10.1159/000487128

DO - 10.1159/000487128

M3 - Article

AN - SCOPUS:85042136446

SN - 1662-6575

VL - 11

SP - 119

EP - 124

JO - Case Reports in Oncology

JF - Case Reports in Oncology

IS - 1

ER -

Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma

Abstract

Keywords

Access to Document

Fingerprint

Cite this